RENALYTIX PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.5 GBX | -3.92% |
|
-18.33% | +58.06% |
| 18/04 | Renalytix chief business officer to become president | AN |
| 18/04 | Renalytix Names Chief Business Officer as President | MT |
| Sales 2024 * | 4M 334M | Sales 2025 * | 18M 1.5B | Capitalization | 47.11M 3.93B |
|---|---|---|---|---|---|
| Net income 2024 * | -35M -2.92B | Net income 2025 * | -26M -2.17B | EV / Sales 2024 * | 11.8 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.62 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Renalytix Plc
More recommendations
More news
| 1 day | -3.92% | ||
| 1 week | -18.33% | ||
| Current month | -26.87% | ||
| 1 month | -30.00% | ||
| 3 months | +108.51% | ||
| 6 months | -40.24% | ||
| Current year | +58.06% |
1 week
24.00
29.60
1 month
24.0035.00
Current year
10.0074.90
1 year
10.00150.00
3 years
10.001 220.00
5 years
10.001 220.00
10 years
10.001 220.00
| Managers | Title | Age | Since |
|---|---|---|---|
James McCullough
FOU | Founder | 56 | 15/18/15 |
James Sterling
DFI | Director of Finance/CFO | 54 | 15/18/15 |
Thomas McLain
PSD | President | 66 | 29/19/29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 30/21/30 |
| Chairman | 72 | 15/18/15 | |
James McCullough
FOU | Founder | 56 | 15/18/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 24.5 | -3.92% | 170,170 |
| 25/24/25 | 25.5 | -3.77% | 43,867 |
| 24/24/24 | 26.5 | -3.64% | 105,921 |
| 23/24/23 | 27.5 | -5.17% | 248,283 |
| 22/24/22 | 29 | -3.33% | 4,852 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotes
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Companyâs lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Calendar
11/06/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.245
Average target price
-
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +58.06% | 47.11M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- RENX Stock
